The Searle Co. Ltd. (SEARL) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor Management Efficiency with a low ROCE of 10.09%

The company has been able to generate a Return on Capital Employed (avg) of 10.09% signifying low profitability per unit of total capital (equity and debt)

High Debt Company with a Debt to Equity ratio (avg) at 0 times

Poor long term growth as Operating profit has grown by an annual rate -10.51% of over the last 5 years

Flat results in Mar 25

With ROE of 8, it has a attractive valuation with a 1.5 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

PKR 66,398 Million (Large Cap)

P/E

78.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.22

Return on Equity

4.31%

Price to Book

2.01

Revenue and Profits:

Net Sales:

7,001 Million

(Quarterly Results - Mar 2025)

Net Profit:

161 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-6.15%

6 Months

-28.11%

1 Year

53.14%

2 Years

122.57%

3 Years

9.72%

4 Years

-40.6%

5 Years

-20.19%

The Searle Co. Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

7.79%

EBIT Growth (5y)

-2.14%

EBIT to Interest (avg)

2.12

Debt to EBITDA (avg)

3.02

Net Debt to Equity (avg)

0.24

Sales to Capital Employed (avg)

0.61

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

10.09%

ROE (avg)

7.89%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.93

EV to EBIT

21.35

EV to EBITDA

16.79

EV to Capital Employed

1.76

EV to Sales

2.43

PEG Ratio

Dividend Yield

ROCE (Latest)

8.24%

ROE (Latest)

2.48%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is -5.02% vs -3.32% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is -66.16% vs 65.92% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7,000.90",
          "val2": "7,370.70",
          "chgp": "-5.02%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "523.80",
          "val2": "1,293.80",
          "chgp": "-59.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "362.50",
          "val2": "646.90",
          "chgp": "-43.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "161.50",
          "val2": "477.20",
          "chgp": "-66.16%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "51.60%",
          "val2": "144.10%",
          "chgp": "-9.25%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2024 is 13.97% vs -13.75% in Jun 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2024 is 2,864.33% vs -101.47% in Jun 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'24",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "29,400.70",
          "val2": "25,796.40",
          "chgp": "13.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "5,461.40",
          "val2": "4,373.70",
          "chgp": "24.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3,615.90",
          "val2": "3,231.10",
          "chgp": "11.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "284.20",
          "val2": "20.40",
          "chgp": "1,293.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "984.10",
          "val2": "-35.60",
          "chgp": "2,864.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "157.40%",
          "val2": "143.20%",
          "chgp": "1.42%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ

Mar'25

Dec'24

Change(%)

Net Sales

7,000.90

7,370.70

-5.02%

Operating Profit (PBDIT) excl Other Income

523.80

1,293.80

-59.51%

Interest

362.50

646.90

-43.96%

Exceptional Items

0.00

Consolidate Net Profit

161.50

477.20

-66.16%

Operating Profit Margin (Excl OI)

51.60%

144.10%

-9.25%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2025 is -5.02% vs -3.32% in Dec 2024

Consolidated Net Profit

QoQ Growth in quarter ended Mar 2025 is -66.16% vs 65.92% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Jun'24

Jun'24

Jun'23

Change(%)

Net Sales

29,400.70

25,796.40

13.97%

Operating Profit (PBDIT) excl Other Income

5,461.40

4,373.70

24.87%

Interest

3,615.90

3,231.10

11.91%

Exceptional Items

284.20

20.40

1,293.14%

Consolidate Net Profit

984.10

-35.60

2,864.33%

Operating Profit Margin (Excl OI)

157.40%

143.20%

1.42%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Jun 2024 is 13.97% vs -13.75% in Jun 2023

Consolidated Net Profit

YoY Growth in year ended Jun 2024 is 2,864.33% vs -101.47% in Jun 2023

All Annual Results

Company CV

About The Searle Co. Ltd.

The Searle Co. Ltd.

Pharmaceuticals & Biotechnology

The Searle Company Limited is a holding company, which is principally engaged in the manufacture of pharmaceutical products and other consumer products. In addition, the Company is engaged in sale of food and consumer products, and manufacture of pharmaceutical products for other companies. The Company operates through three segments: Pharma, Consumer and Investment property. The Company's geographical segments include Pakistan, South Asia, East Africa, South-East Asia and Middle East. The Company's portfolio includes three divisions: Pharma, Consumer Health and Nutrition. Its products include Selanz SR, Levoxin, Lomotil, Xaroban, Vitrum, Rhulef, Canderel, Peditral, Ezium, Hydryllin, Xadine, Zenbar, Extor, Adronil, Nuberol/Nuberol Forte and Byscard. The Company has pharmaceutical range across therapeutic areas, such as cardiovascular, respiratory care, gastroenterology, pain management, orthocare, neuropsychiatry, probiotics, antibiotics and nutritional care.

Company Coordinates

Company Details

1st Floor, N.I.C. Building, Abbasi Shaheed Road KARACHI None : 75530

Tel: 92 21 35674321

https://www.searlecompany.com/

Registrar Details